logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
How developing world concerns need to be part of drug development plans: A case study of four emerging antiretrovirals | Journal Article / Research | MSF Science Portal
Journal Article
|Research

How developing world concerns need to be part of drug development plans: A case study of four emerging antiretrovirals

van Roey J, von Schoen-Angerer T, Ford NP, Calmy A
Download

Similar Content
Loading...
Loading...
Loading...
Abstract
Clinical trials are usually designed to meet registration requirements in developed countries, and do not always address key concerns for use in developing countries. Four late-stage investigational new drugs - rilpivirine, etravirine, raltegravir and maraviroc - show potential to improve antiretroviral therapy. However, a number of issues could limit their use in developing countries, including dose selection, treatment strategy, combination with other drugs, use in specific populations and reliance on expensive tests. Key research questions relevant for developing countries need to be answered early in the drug development process to ensure maximum benefit for the majority.

Languages

English
DOI
10.1016/j.drudis.2008.04.009
Published Date
01 Jul 2008
PubMed ID
18598916
Journal
Drug Discovery Today
Volume | Issue | Pages
Volume 13, Issue 13-14
Issue Date
2008-07-01
Dimensions Badge